| 马秀杰,曲相珍,乔小东,刘艳丽,张庆博.阿托伐他汀钙片治疗脑梗死的疗效及其对MMP-2表达的影响[J].现代生物医学进展英文版,2022,(16):3188-3192. |
| 阿托伐他汀钙片治疗脑梗死的疗效及其对MMP-2表达的影响 |
| Efficacy of Atorvastatin Calcium Tablets in the Treatment of Cerebral Infarction and Its Effect on the Expression of MMP-2 |
| Received:February 06, 2022 Revised:February 28, 2022 |
| DOI：10.13241/j.cnki.pmb.2022.16.038 |
| 中文关键词: 阿托伐他汀 脑梗死 基质金属蛋白酶-2 |
| 英文关键词: Atorvastatin Cerebral infarction Matrix metalloproteinase-2 |
| 基金项目:内蒙古自治区自然科学基金项目（2018MS08067） |
|
| Hits: 717 |
| Download times: 363 |
| 中文摘要: |
| 摘要 目的：探讨阿托伐他汀钙片治疗脑梗死的疗效及其对基质金属蛋白酶（MMP-2）表达的影响。方法：选择2019年5月-2021年2月在本院诊治的脑梗死患者64例，根据随机信封抽签原则将患者分为阿托伐他汀组32例与对照组32例。对照组给予常规双抗治疗，阿托伐他汀组以对照组为基础给予阿托伐他汀治疗，两组都治疗观察3个月，记录MMP-2表达的变化。结果：治疗后阿托伐他汀组的总有效率为93.8 %，高于对照组的68.8 %（P<0.05）。两组治疗后的低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）、总胆固醇（TC）水平均低于治疗前（P<0.05），高密度脂蛋白胆固醇（HDL-C）水平高于治疗前（P<0.05），组间对比无差异（P>0.05）。两组治疗后的大脑中动脉平均血流速度（Vm）明显高于治疗前，搏动指数（PI）明显低于治疗前，阿托伐他汀组与对照组对比差异明显（P<0.05）。两组治疗后的血清MMP-2含量低于治疗前，阿托伐他汀组低于对照组（P<0.05）。两组治疗期间的不良反应主要为恶心呕吐、低血压、静脉血栓、头晕脑胀，组内对比无差异（P>0.05）。结论：阿托伐他汀治疗脑梗死能降低MMP-2水平，可在平衡血脂水平的基础上提高患者的治疗效果，还可提高大脑中动脉的血流速度，且为增加不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the efficacy of atorvastatin calcium tablets in the treatment of cerebral infarction and its effect on the expression of matrix metallo protease (MMP)-2. Methods: From May 2019 to February 2021, A total of 64 cases of patients with cerebral infarction who were diagnosed and treated in our hospital were selected. All the cases were divided into atorvastatin group with 32 cases and matched group with 32 cases in each groups accorded to the principle of random envelope drawing. The matched group were given conventional dual-antibody therapy, and the atorvastatin group were given atorvastatin treatment on the basis of the treatment of the matched group. Both groups were treated for 3 months, and the changes of MMP-2 expression were recorded. Results: Post-treatment, the total effective rates in the atorvastatin group were 93.8 %, which were higher than that in the matched group (68.8 %) (P<0.05). The levels of low density lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol (TC) post-treatment in both groups were lower than those pretherapy, the level of low-density lipoprotein cholesterol (HDL-C) were higher than that pretherapy, and there were no difference compared between the groups (P>0.05). The mean blood flow velocity (Vm) of the middle cerebral artery in the two groups post-treatment were higher than that pretherapy, and the pulsatility index (PI) were lower than that pretherapy, compared with the matched group, the difference were also significant (P<0.05). The levels of serum MMP-2 in the two groups post-treatment were lower than those pretherapy, and those in the atorvastatin group were lower than those in the matched group (P<0.05). The main adverse reactions during treatment in the two groups were nausea and vomiting, hypotension, venous thrombosis, dizziness and brain swelling, and there were no significant difference compared between the two groups (P<0.05). Conclusion: Atorvastatin in the treatment of cerebral infarction can reduce the level of MMP-2, improve the therapeutic effect of patients on the basis of balancing the blood lipid level, and also increase the blood flow velocity of the middle cerebral artery without increasing the occurrence of adverse reactions. |
|
View Full Text
View/Add Comment Download reader |
| Close |
